Fact CheckerSign in

NCT05218772Completed

Objective and Perceived Health Status of Elderly People With Moderate or Severe Haemophilia in France: an Ancillary Study of the FranceCoag Registry

Source: ClinicalTrials.gov · Last updated 8 Oct 2026

Brief summary (registry, in English)

Background: Elderly people with serious haemophilia (PwSH), i.e., with moderate or severe haemophilia, have major comorbidities due to consequences of haemophilia. Also, the comorbidities related to age are added. Despite the existence of numerous studies on the objective health status of elderly PwSH, some limitations may be stated (need to update the results in a more contemporary context, no studies conducted in France, highlighted determinants focused on demographic and clinical factors). On the contrary, the perceived health status of elderly PwSH has been little described. Only two studies specifically addressed the quality of life (QoL) of elderly PwSH. These studies reported an altered QoL in some domains, in comparison with reference values from the general population. However, some limitations may also be stated (need to bring results in a more contemporary context, no studies conducted in France, highlighted determinants focused on clinical factors). Since serious haemophilia is a rare disease, studies are often performed on a small number of subjects. The present project relies on the FranceCoag registry, a unique exhaustive national cohort of PwSH followed over time among whom 612 are elderly PwSH. Objectives: Main objective: to describe the objective and perceived health status of elderly (≥60 y.o.) PwSH from of a French exhaustive national registry, and to compare their health status with that of the French general elderly population. Secondary objective: to identify individual (demographic, clinical, social, psycho-cognitive) and collective characteristics (related to healthcare organisation), associated with the objective and perceived health status of elderly PwSH in France. Materials and Methods: A national, multicentric, observational, cross-sectional study will be conducted. It will be based on the participation of elderly PwSH already included in the FranceCoag registry. Each eligible participant will receive a questionnaire to complete concerning: objective health status; perceived health status (QoL assessed by the WHOQOL-Old questionnaire); demographic data; social data; psycho-cognitive data (anxious symptoms, depressive symptoms, use of coping strategies, time perspective). Therapeutic and clinical data related to haemophilia will be collected via the FranceCoag registry database. Data concerning healthcare organisation will be collected directly from investigators of Haemophilia Treatment Centres. The main analysis will consist in the description and comparison of the health status with reference data from the French general elderly population. Standardisation methods will be used to take into account a potential imbalance between the study population and the reference population, related to age and especially to sex, as haemophilia is a predominantly male disease. The secondary analysis will consist in the identification of potential determinants of the health status. Structural equation models will be performed to take into account the complexity of the relationships between the determinants. Impact of the proposal Better understanding the impact of the disease on patients' experience is essential in a systematic global perspective of health, that aims to care and support the individual not only as a patient but also as a person in his/her environment. This study based on a registry will allow to improve the knowledge by updating literature data on the health status of elderly PwSH, adding elements to the rare literature data on the perceived health status, providing data in the French specific context, and identifying both classical and more original determinants of health status of elderly PwSH. These results will be used to better identify elderly PwSH at high risk of poor health status, to propose recommendations and to set up actions to offer them an adapted support, and to elaborate new versions of public health plans dedicated to haemophilia or to rare diseases.

Status (registry)
Completed
Study type
Observational
Enrollment
277 (actual)
First submitted
20 Jan 2022
Start date
19 Apr 2022
Primary completion date
30 Jun 2023
Lead sponsor
Assistance Publique Hopitaux De Marseille
Diseases
Haemophilia
NCT number
NCT05218772

What you commit to

  • Study type: Observational
  • Participants enrolled: 277
  • From 19 Apr 2022 to the primary completion date, 30 Jun 2023
  • 28 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • People with comprehension disabilities;
  • Participants who a posteriori oppose to participate in the study.

Who the study is looking for

  • People with serious haemophilia, i.e., with (A or B) moderate or severe haemophilia;
  • People aged 60 years or over;
  • People included in the FranceCoag registry;
  • People followed in one of the Haemophilia Treatment Centre participating in the study;
  • People who do not oppose to participate in the study.

Age in the registry: 60 years to 100 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (28)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
CHU Amiens
Coordinator of this site? Confirm its status
AmiensFranceUnknown status
Ch Annecy - St Julien
Coordinator of this site? Confirm its status
AnnecyFranceUnknown status
CHU de Besançon
Coordinator of this site? Confirm its status
BesançonFranceUnknown status
CHU de Bordeaux
Coordinator of this site? Confirm its status
BordeauxFranceUnknown status
Chu Brest
Coordinator of this site? Confirm its status
BrestFranceUnknown status
CHU de CAEN
Coordinator of this site? Confirm its status
CaenFranceUnknown status
Centre Hospitalier Métropole Savoie
Coordinator of this site? Confirm its status
ChambéryFranceUnknown status
CHU Clermont-Ferrand
Coordinator of this site? Confirm its status
Clermont-FerrandFranceUnknown status
CHU de DIJON
Coordinator of this site? Confirm its status
DijonFranceUnknown status
Chu La Reunion
Coordinator of this site? Confirm its status
La RéunionFranceUnknown status
CHU le MANS
Coordinator of this site? Confirm its status
Le MansFranceUnknown status
CHRU de Lille
Coordinator of this site? Confirm its status
LilleFranceUnknown status
Hospices Civils de Lyon
Coordinator of this site? Confirm its status
LyonFranceUnknown status
AP-HM
Coordinator of this site? Confirm its status
MarseilleFranceUnknown status
CHU Montpellier
Coordinator of this site? Confirm its status
MontpellierFranceUnknown status
CHU de Nancy
Coordinator of this site? Confirm its status
NancyFranceUnknown status
CHU Nantes
Coordinator of this site? Confirm its status
NantesFranceUnknown status
CHU de Nice
Coordinator of this site? Confirm its status
NiceFranceUnknown status
AP HP
Coordinator of this site? Confirm its status
ParisFranceUnknown status
CHU Poitiers
Coordinator of this site? Confirm its status
PoitiersFranceUnknown status
CHU Reims
Coordinator of this site? Confirm its status
ReimsFranceUnknown status
CHU de Rennes
Coordinator of this site? Confirm its status
RennesFranceUnknown status
CHU de Rouen
Coordinator of this site? Confirm its status
RouenFranceUnknown status
Chu St-Etienne
Coordinator of this site? Confirm its status
Saint-EtienneFranceUnknown status
CHU Strasbourg
Coordinator of this site? Confirm its status
StrasbourgFranceUnknown status
CHU Toulouse
Coordinator of this site? Confirm its status
ToulouseFranceUnknown status
CHRU de Tours
Coordinator of this site? Confirm its status
ToursFranceUnknown status
Ch Versailles
Coordinator of this site? Confirm its status
VersaillesFranceUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.